Dr. Lal PathLabs Ltd

Uzbekistan subsidiary formation

• Dr Lal PathLabs FZCO subscribes to 70% of the newly incorporated entity in Uzbekistan.
• The subsidiary is named Dr Lal PathLabs Indomed LLC and is based in Tashkent.
• Dr Lal PathLabs FZCO will hold 70% of the subsidiary's share capital.
• Cash consideration will be paid at face value.
• Incorporation date of the subsidiary: August 19, 2026.
• The venture aims to strengthen the Group's diagnostics presence in Tashkent.
• Turnover for the entity is not applicable as it is newly incorporated.

Capital / Securities

• Board approved allotment of 211,050 ESOP shares under ESOP Plan 2022 on Aug 06, 2026.
• Paid-up equity capital increased to INR 1,67,84,88,200, comprising 16,78,48,820 shares of INR 10.

Financial Performance

• Revenue for Q1 FY27: Rs 798 crore, up 19.1% YoY.
• EBITDA: Rs 247 crore, margin 31.0%.
• PBT: Rs 229 crore, margin 28.7%.
• PAT: Rs 170 crore, margin 21.4%.
• EPS: Rs 10.1, up 27.8%.
• Revenue per patient: Rs 968, up 10%.
• Test per patient: 3.14, up from 3.07.
• Interim dividend declared: 50% (Rs 5 per share).
• Net cash and equivalents: Rs 1,693 crore as of June 30, 2026.

Operational Highlights

• Patient volumes: 8.2 million, up 8.2%.
• Samples: 25.9 million, up 10.7%.
• 116 new tests launched; 81 genomics assays; four first-in-India tests.
• SwasthAI WhatsApp bot launched to improve booking journeys.
• WES turnaround times: 15 days; Express WES: 10 days.
• Routine tests (~400) delivered in 3 hours for ~90% walk-ins.
• Dubai subsidiary incorporation marks international expansion milestone.

M&A and Capital Allocation

• Acquisition: 80% stake in Sunshine Healthcare Ltd, Ghana; cap not exceeding GHS 45.6 million.
• Acquisition: 30% stake in Neuome Technologies; Rs 3.5 crore.
• Cash deployment: primarily for M&A and high-end radiology centers.
• Capex guidance: Rs 140–150 crore for this year and next.
• Near-term international contribution not targeted; focus on Africa, Middle East, CIS, Southeast Asia.

Guidance and Outlook

• Q1 ahead of forecast; expects mid-teens revenue growth for FY27 after H1 review.
• CGHS uplift of 2-3% realized; likely continues 2-3 quarters.
• Pricing increase not planned in H1; reassessment at year-end.
• Swasthfit contribution near 20% remains; higher realization tests support.
• International contribution below 5%; improving gradually over 3-5 years.

Risks and Watchpoints

• Weather patterns affected Q1 volumes; impact uncertain for next quarters.
• Currency and inflation may raise material costs; realizations may offset margins.
• International expansion is longer-term with execution risk.

AGM Details

• AGM held 25 July 2026 at 10:00 IST via Video Conference/OAVM.
• Record date 18 July 2026.

Resolutions & Voting

• Resolution 1: Adopt financial statements; passed (99.87% in favour).
• Resolution 2: Final dividend of INR 4 per share; passed (100% in favour).
• Resolution 3: Appoint Rahul Sharma by rotation; passed (99.31% in favour).
• Resolution 4: Remuneration revision for Arvind Lal; passed (100%).
• Resolution 5: Remuneration revision for Vandana Lal; passed (100%).
• Resolution 6: Re-appoint Arvind Lal as Exec Chairman for 5 years from 2027; passed (99.80%).
• Resolution 7: Re-appoint Rajit Mehta as NED Independent for second term; passed (99.66%).
• Resolution 8: Remuneration to Rahul Sharma on ESOP exercise; passed (99.59%).
• Resolution 9: Payment of Commission to Non-Executive Directors; passed (99.99%).
• Resolution 10: Ratify Cost Auditors’ remuneration for 2026-27; passed (99.999%).

Dividend

• Final dividend of INR 4 per fully paid equity share approved.

Directors & Auditors

• Arvind Lal re-appointed as Executive Chairman for five years from 01-Apr-2027.
• Rajit Mehta re-appointed as Non-Executive Independent Director for a five-year term.
• Remuneration revisions approved for Arvind Lal and Vandana Lal.
• Cost Auditors’ remuneration for 2026-27 ratified.

Related Party & Other Approvals

• No material related party transactions disclosed.
• All other AGM approvals completed.

AGM Details

• Date and time: 25 July 2026 at 10:00 IST.
• Mode: VC/OAVM as per MCA guidance.
• AGM concluded at 11:03 IST; e-voting remained open for 15 minutes.

Resolutions put to vote

• Ordinary: Adopt standalone and consolidated financial statements for year ended 31 March 2026.
• Ordinary: Declare final dividend of INR 4 per equity share.
• Ordinary: Re-appoint Rahul Sharma as Director, retiring by rotation.
• Special: Remuneration revision for Arvind Lal, Executive Chairman and Whole-Time Director.
• Special: Remuneration revision for Vandana Lal, Whole-Time Director.
• Special: Re-appoint Arvind Lal as Executive Chairman/WD for five years from 1 Apr 2027.
• Special: Re-appoint Rajit Mehta as Non-Executive Independent Director for second five-year term.
• Special: Remuneration to Rahul Sharma on ESOP exercise exceeding 50%.
• Special: Payment of Commission to Non-Executive and Independent Directors.
• Ordinary: Ratify remuneration payable to Cost Auditors for FY 2026-27.

Dividend

• Final dividend of INR 4 per share.

Director changes

• Rahul Sharma re-appointed as Director, rotating.
• Arvind Lal re-appointed as Executive Chairman and Whole-Time Director for five years from Apr 1, 2027.
• Rajit Mehta re-appointed as Non-Executive Independent Director for second five-year term.

Auditors & remuneration

• Cost Auditors remuneration for FY 2026-27 ratified.

Voting status

• Voting results to be announced on or before 28 July 2026.
• Results to be posted on company and exchange websites.

Tax appellate outcome

• Appellate order dated July 16, 2026 allows ESOP deduction of INR 32,66,18,927.
• Appeal against March 31, 2024 IT assessment decided in company's favour.

Meeting Details

• Date and time: Friday, July 24, 2026 at 5:30 PM IST.
• Type and mode: Group virtual earnings conference call.
• Event: Q1 FY27 Earnings Conference Call.
• Key participants: Executive Chairman; CEO; Group CFO & CEO – International Business.
• Purpose: Discuss Q1 FY27 results and performance; Q&A session.
• Pre-registration required; dial-in details provided after registration.

Meeting Details

• Date: July 24, 2026 (Friday)

Key Agenda Items

• Unaudited standalone and consolidated financial results for quarter ended June 30, 2026.
• Interim dividend, if any, on equity shares for FY 2026-27.

Dematerialisation status

• No demat/rematerialisation requests were received during the quarter ended 30 June 2026.
• Company has no physical shares; no physical certificates were received for dematerialisation.